Alterity Therapeutics (ATH)
83.33
0.00 (0.00%)
Upcoming Events
Latest Headlines
Athabasca Oil closes $500 million credit facility, boosts liquidity to $870 million
June 1, 2026 8:02 AM - StreetInsider
Athabasca Oil Corporation Announces New $500 Million Four-Year Credit Facility and Expanded Duvernay Energy Credit Facility
June 1, 2026 8:01 AM - Globe NewsWire
Alterity Therapeutics presents data supporting ATH434 Phase 3 advance in MSA
May 19, 2026 7:25 AM - StreetInsider
Alterity Therapeutics Data Presentations Support Advancement of ATH434 into Phase 3 in Multiple System Atrophy
May 19, 2026 7:25 AM - Globe NewsWire
Alterity Therapeutics Announces Publication Demonstrating the Utility of Quantitative MRI as a Biomarker for Multiple System Atrophy
May 11, 2026 7:25 AM - Globe NewsWire
Athabasca Oil Corporation Announces Results from 2026 Annual Shareholder Meeting
May 7, 2026 4:36 PM - Globe NewsWire
Alterity Therapeutics to Deliver Presentations at Multiple Medical Conferences in May 2026
May 7, 2026 7:25 AM - Globe NewsWire
Athabasca Oil Reports Strong 2026 First Quarter Results and Increased Cash Flow Outlook
May 6, 2026 7:51 PM - Globe NewsWire
Athene Expands Registered Index-Linked Annuity (RILA) Lineup with Launch of Athene Amplify® 3.0
May 4, 2026 7:45 AM - Globe NewsWire
Alterity Therapeutics Releases Appendix 4C – Q3 FY26 Quarterly Cash Flow Report & Corporate Update
April 30, 2026 7:25 AM - Globe NewsWire
Athene Holding Ltd. Declares Second Quarter 2026 Preferred Stock Dividends
April 29, 2026 4:17 PM - Globe NewsWire
Alterity Therapeutics receives FDA alignment on ATH434 manufacturing plans
April 27, 2026 7:25 AM - StreetInsider
Alterity Therapeutics Receives Positive FDA Feedback Following Second Type C Meeting on ATH434 Phase 3 Program in Multiple System Atrophy
April 27, 2026 7:25 AM - Globe NewsWire
Alterity Therapeutics shares new ATH434 trial data at neurology meeting
April 22, 2026 7:25 AM - StreetInsider
Alterity Therapeutics Presents New Analysis of ATH434 Phase 2 Trial Data in Late Breaking Science Session of the American Academy of Neurology
April 22, 2026 7:25 AM - Globe NewsWire
Athene Announces First Quarter 2026 Fixed Income Investor Call
April 21, 2026 7:45 AM - Globe NewsWire
Alterity Therapeutics appoints Ann Cunningham to board of directors
April 17, 2026 7:25 AM - StreetInsider
Alterity Therapeutics Appoints Highly Experienced Biotech Executive Ann Cunningham to its Board of Directors
April 17, 2026 7:25 AM - Globe NewsWire
Alterity Therapeutics Announces Late-Breaker Oral Presentation at the American Academy of Neurology Annual Meeting
April 16, 2026 11:41 AM - Globe NewsWire
Alterity Therapeutics to Host Virtual KOL Event to Share New Insights on ATH434 for the Treatment of Multiple System Atrophy
April 15, 2026 7:25 AM - Globe NewsWire
Athabasca Oil Announces Renewal of Normal Course Issuer Bid
March 16, 2026 8:01 AM - Globe NewsWire
Full Article List
